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Propylthiouracil- (PTU-) induced hepatotoxicity is rare but potentially lethal with a spectrum of liver injury ranging from
asymptomatic elevation of transaminases to fulminant hepatic failure and death. We describe two cases of acute hepatic failure due
to PTU that required liver transplantation. Diﬀerences in the clinical presentation, histological characteristics, and posttransplant
management are described as well as alternative therapeutic options. Frequent monitoring for PTU-induced hepatic dysfunction
is strongly advised because timely discontinuation of this drug and implementation of noninvasive therapeutic interventions may
prevent progression to liver failure or even death.
1.Introduction
Propylthiouracil(PTU)hasbeenimplicatedindrug-induced
liver injury (DILI) in patients with hyperthyroidism treated
with this medication. Reported injury has ranged from mild
asymptomatic elevation of aminotransferases to acute liver
failure (ALF). Although asymptomatic elevations in hepatic
enzymes have been described in patients with untreated
hyperthyroidism, recognition of hepatic dysfunction in a
patient taking PTU requires immediate discontinuation of
the drug and close followup.
2. CasePresentations
Case 1. A 29-year-old African American woman with
Graves’ disease unsuccessfully treated with methimazole was
prescribed propylthiouracil (PTU) 50mg PO every 8 hours.
Aminotransferase levels were normal before therapy was
started; however, mild elevations of these enzymes were
initially noticed by the fourth week of therapy (AST:
64U/L, ALT: 94U/L, alkaline phosphatase: 170U/L) and
continued to progressively increase by week eight. By week
ten of treatment, she reported jaundice, fatigue, epigastric2 International Journal of Endocrinology
abdominal pain, nausea, and vomiting. She denied the
use of over-the-counter or herbal medications. Her past
medical history and family history were not contributory.
She denied excessive alcohol consumption and recreational
drug use. Upon subsequent transfer to our institution,
initial laboratory workup revealed a prothrombin time of
39.1 seconds, INR 3.9, total bilirubin 19.3mg/dL, direct
bilirubin 12.1mg/dL, AST 503U/L, ALT 443U/L, alka-
line phosphatase 509U/L, TSH 0.013µIU/ml, and free-T4
0.7ng/dL. Serum markers for viral hepatitis A, B, and C
were negative. Antinuclear antibodies, antismooth muscle
antibodies, and antimitochondrial antibodies were negative.
PTU was discontinued, but the coagulopathy worsened,
and she subsequently developed hepatic encephalopathy.
She underwent orthotopic liver transplantation (OLT) eight
days following admission. Histologic examination of the
explanted liver revealed submassive, conﬂuent necrosis with
parenchymal hemorrhage, bile duct proliferation, intracellu-
lar and canalicular cholestasis, bile plugging, and severe lym-
phoplasmacytic and eosinophilic inﬁltrates. Immunostain
for IgG4 was positive (Figure 1, microphotographs (a) and
(b)).Thepatientwasdischargedhomeinstableconditionon
postoperative day twelve. Her liver function become normal
6 months following OLT.
Case2. A34-year-oldAfricanAmericanwomanwithGraves’
disease and without an antecedent history of liver disease
was prescribed PTU 150mg PO twice daily. Baseline levels
of aminotransferases were normal at the time PTU was
started. Six weeks later she started to complain of malaise
and generalized weakness followed by progressive jaundice,
but she did not seek medical care until two weeks later when
she had developed confusion, nausea, and vomiting. Blood
tests at that time were INR 4.3, total bilirubin 22.8mg/dL,
direct bilirubin 10.8mg/dL, AST 1081U/L, ALT 1227U/L,
alkaline phosphatase 272U/L, TSH 61.2µIU/ml, and free-
T4 0.6ng/dL. Serum markers for autoimmune and viral
hepatitis A, B, and C were negative. PTU was discontinued;
however, her mental status continued to deteriorate with
progression to severe hepatic encephalopathy. A transjugular
liver biopsy revealed extensive parenchymal necrosis, col-
lapse of the lobular architecture, bile duct proliferation,
and periportal inﬂammation. Two days after admission,
she was listed for OLT and received a liver transplant
three days later. Histological examination of the native
liver showed submassive conﬂuent necrosis with prominent
eosinophilic, neutrophilic, and lymphoplasmacytic inﬁltrate
with canalicular and intracellular cholestasis and numerous
lobular acidophilic bodies (Figure 1, microphotographs (c)
and (d)). The allograft was retrieved from a 77-year-old
deceased donor, due to the recipient’s critical status. The
posttransplant course was complicated by the development
of graft dysfunction due to severe rejection, which did not
improve with aggressive immunosuppressive therapy. The
patient was relisted for OLT two weeks after the initial
transplant and received a second allograft 6 days later.
The postoperative course after the second transplant was
complicated by a biliary leak that required reconstruction
of the biliary anastomosis, as well as multiple episodes
of rejection which were treated with antilymphocyte anti-
bodies, plasmapheresis, and administration of rituximab.
The patient eventually recovered. She was discharged on
postoperative day 155 from the ﬁrst liver transplant and is
currently at home doing well 6 months after the second liver
transplant.
3. Discussion
PTU is a thioamide derivative widely used for the treatment
of hyperthyroidism which exerts its pharmacologic eﬀects
by two diﬀerent mechanisms. It inhibits reactions catalyzed
by the enzyme thyroid peroxidase expressed in the thyroid
follicles and blocks iodine organiﬁcation, and it also inhibits
the enzyme 5-deiodinase accountable for the peripheral
conversion of T4 into the active T3 moiety.
PTU-induced hepatitis was ﬁrst reported by H. J. Liv-
ingstonandS.F.Livingstonin1947[1],shortlyaftertheFDA
had approved this medication for the treatment of hyper-
thyroidism. This patient was successfully managed with sup-
portive care after discontinuation of the drug. Six years later,
Eisen [2] reported the ﬁrst case of fulminant hepatic failure
attributed to PTU, an ominous adverse reaction that since
then has been observed in an extremely small number of
patients receiving this medication. Based on published data
about the annual incidence of hypothyroidism, the reported
frequency of PTU therapy (15,000 adults per year), and the
incidence of PTU-induced severe liver injury (approximately
0.1% in the adult population), approximately 15 adults will
develop this complication annually in USA and 10% of
them (1:10,000 adults) will progress to ALF. Asymptomatic
elevations of alanine aminotransferase (ALT) are observed
in 14–28% of patients started on PTU during the ﬁrst 2
months of therapy and usually resolve with no intervention
[3]. Acute hepatitis associated with this medication has been
reported to occur in 0.1–1.2% of patients [4]. The mortality
associated with PTU-induced acute hepatitis can be as high
as25%[5].Datasuggestthattheriskofseverehepatotoxicity
is greater in children treated with PTU (1:1,000 children),
but the overall incidence is signiﬁcantly lower because fewer
children are treated with this drug (1,500–4,000 children per
year) [6]. For example, a signiﬁcant reduction in PTU use by
pediatric endocrinologists has been observed over the past
several years, and some authors advocate that PTU should
never be used as a ﬁrst-line therapy in children due to the
potential risk severe hepatotoxicity [7].
Liver biopsy remains the gold standard for diagnosis
of PTU-induced hepatic injury, but the diagnosis is often
inferred from the time course after initiation of PTU
therapy [5, 8]. PTU hepatotoxicity has been reported to
cause a variety of histological changes including portal and
periportalinﬂammationwitheosinophilic,lymphocytic,and
plasmacytic inﬁltration in varying combinations, chronic
active hepatitis, and submassive or massive hepatic necro-
sis [9]. These histological features resemble autoimmune
hepatitis type 1 (AIH-1) and are referred to as drug-
induced AIH-1. A multifactorial hypothesis has been pro-
posed as an explanation for PTU-induced hepatopathy inInternational Journal of Endocrinology 3
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Figure 1: (a) Submassive conﬂuent necrosis with hemorrhage (H & E, 40x). (b) Periportal bile duct proliferation and mixed inﬂammatory
inﬁltrate (H&E, 100x). (c) Residual hepatocytes with cholestasis, acidophilic bodies, and mononuclear inﬂammation (H&E, 400x). (d)
Eosinophilic and lymphoplasmacytic inﬁltrate (H&E, 400x).
which inhibition of glucuronyl transferase, reduced bile
acid synthesis, and increased oxygen consumption by the
hepatocytes could be implicated in more or less extent
[10, 11]. Severe PTU-induced hepatotoxicity is postulated
to be a dose independent, idiosyncratic hypersensitivity
reaction. This theory is supported by positive lymphocyte
sensitization studies [3, 4, 12]. Some authors have noted an
association between this pathologic condition and positive
antineutrophil cytoplasmic antibodies (ANCA); however,
ANCA positivity has been reported in up to 50% of
asymptomatic patients receiving PTU, and this ﬁnding has
been considered to be incidental in the majority of cases and
not directly related to DILI or ANCA-associated vasculitis
[13, 14].
Treatment options for PTU-induced liver failure are lim-
ited. Immediate discontinuation of the drug is imperative,
but progression of liver injury may occur, particularly in
cases with severe forms of DILI, and aggressive supportive
care is usually required. The milder form of PTU-induced
hepatotoxicity, characterized by symptomatic hepatitis, has
beenassociatedwithcompleterecoveryafterdiscontinuation
of the drug [15]. This outcome has also been reported in
cases with cholestatic liver injury, although the time required
for normalization of biochemical markers was longer in
the latter group [4]. Some authors have suggested that
the coincidental clinical improvement in patients receiving
systemic corticosteroids for the treatment of thyrotoxicosis
mightreﬂectatherapeuticresponse[16].Plasmapheresiswas
apparently successfully used, in one case report of fulminant
hepatic failure; nonetheless, concomitant use of prednisone
confounded evaluation [8]. Liver transplantation has been
reported in severe, life-threatening cases of PTU-induced
hepatotoxicity with good outcomes [5, 15]. Between 1990
and 2007, the United Network for Organ Sharing (UNOS)
reported 23 liver transplants (16 in adults and 7 in children)
for PTU-induced ALF. Population-based estimates of liver
transplantations for ALF using the UNOS database indicate
that drug-induced ALF accounts for approximately 12–15%
of liver transplants for ALF in USA [17, 18]. PTU is the third
most common single drug responsible for DILI requiring
liver transplantation in the general population, preceded by
acetaminophen and isoniazid in the adult population and by
acetaminophen and valproic acid in pediatric patients [17].
The mean age of patients with PTU-induced ALF is 28 years;
over two thirds of these patients are females and almost half
of them are African Americans. Therefore, African American
ethnicitymaybeariskfactorforsevereformofPTU-induced
hepatotoxicity; nonetheless, there are no data supporting
ethnicity-speciﬁc or genetic variations responsible for these
observations,andspeciﬁcrecommendationsabouttheuseof4 International Journal of Endocrinology
PTU in African Americans cannot be made. ALF secondary
to PTU and herbal substances is associated with higher
bilirubin levels (23.2mg/dL and 23.6mg/dL on average,
resp.) compared to other drugs, including acetaminophen
(9.8mg/dL on average). The one-year graft survival rate after
liver transplantation for PTU-induced ALF is 84%; however,
no signiﬁcant diﬀerence has been found in graft survival
rates after ALF caused by PTU, acetaminophen, isoniazid ,
or phenytoin [17].
We add to the body of literature two more cases of
severe PTU-induced liver failure successfully treated with
OLT. The ﬁrst patient had an uneventful posttransplant
recovery, but the second case had a complicated clinical
course requiring retransplantation and multiple interven-
tions to prevent loss of the second allograft. Extended
criteria for donor organs, including advanced-age donors,
may be used due to the emergency need for OLT in patients
with fulminant hepatic failure; nonetheless, higher rates of
severe complications requiring specialized care underscore
the importance of treating these patients in experienced,
high-volume transplant centers. There are no oﬃcial recom-
mendations regarding monitoring for serologic markers of
liverinjuryduringPTUtherapy;however,someauthorshave
recommended monthly monitoring of serum transaminases
for the ﬁrst six months of therapy, which is the period
where most cases of PTU-induced DILI occur [19, 20].
Although there are no evidence-based data to support this
recommendation, we agree with the suggested time intervals
and duration of monitoring and emphasize the importance
of early discontinuation of therapy when early signs of liver
injury are detected.
4. Conclusions
Clinicians taking care of patients being treated with PTU
should have a low threshold for suspecting medication-
relatedadversereactions,particularlyforPTU-inducedDILI.
Routine monitoring of serum transaminases and close
followup is recommended; nonetheless, the appropriate
intervalsanddurationoffollowuphavenotbeenestablished.
Early identiﬁcation of clinical signs and abnormalities in
biochemical markers of hepatic injury followed by imme-
diate discontinuation of PTU, aggressive supportive care,
and transfer of patients to centers capable of performing
emergent liver transplantation is strongly advised due to
the high mortality associated with severe forms of this
complication.
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